Menu

Detecting SARS-CoV-2 with qPCR

This virtual symposium, brought to you by The Scientist, will explore the limitations and challenges of current SARS-CoV-2 qPCR-based testing approaches, their root causes, and what can be learned for the future.

The Scientist Creative Services Team
Aug 5, 2020

FREE Symposium

Tuesday, September 8, 2020
11:00 AM - 2:00 PM, Eastern Standard Time

Register Now


SARS-CoV-2 has put unprecedented pressure on medical professionals, public health organizations, and the general public. The accurate and timely diagnosis of SARS-CoV-2 infection is paramount to controlling the spread of this virus. This, in turn, relies on the establishment of well-validated testing and detection measures to ensure rapid result dissemination without sacrificing sensitivity and specificity.

This virtual symposium, brought to you by The Scientist, will explore the limitations and challenges of current SARS-CoV-2 qPCR-based testing approaches, their root causes, and what can be learned for the future.


Symposium program

11:00 AM – Basic considerations for SARS-CoV-2 testing by RT-qPCR 
Stephen Bustin, PhD

qPCR data needs to be validated in a standardized manner. In this talk, Dr. Bustin will address qPCR sensitivity, specificity, and efficiency, as well as comment on data robustness and how to best analyze qPCR-derived data for SARS-CoV-2 testing.

11:40 AM – Current standards and validations for SARS-CoV-2 testing 
Jim Huggett, PhD

SARS-CoV-2 arrived in the different regions of the world at different times and in differing magnitudes. As such, SARS-CoV-2 testing responses have been somewhat varied.  Dr. Huggett will speak on the current QA/QC standards for qPCR-based SARS-CoV-2 testing, discuss the limitations and challenges that have been encountered with regard to testing validation and standardization, and explore the root causes for these issues.

12:20 PM – Learning from a pandemic: How do we do it better? 
Mikael Kubista, PhD

SARS-CoV-2 may be unparalleled in impact, but it is far from the first—or last—pandemic to afflict the world. Here, Dr. Kubista will discuss the lessons to be learned from the preparations and responses to SARS-CoV-2 made by various nations, governments, and health entities across the world, as well as the necessary preparations for future waves of SARS-CoV-2 and for future pandemics.

1:00 PM – Open Panel Q&A Session 

Bustin, Huggett, and Kubista will be joined by colleagues Jo Vandesompele and Michael Pfaffl in an open question and answer session where they will address questions posed by the audience.

Register Now


Meet the speakers:

Stephen A. Bustin, PhD
Professor of Molecular Medicine
Faculty of Health, Education, Medicine and Social Care
Anglia Ruskin University

Jim F. Huggett, PhD
Senior Lecturer, Analytical Microbiology
School of Biosciences and Medicine
University of Surrey

Mikael Kubista, PhD
Head, Institute of Biotechnology
Czech Academy of Sciences
Founder and Chairman of the Board
TATAA Biocenter

Jo Vandesompele, PhD
Professor
Department of Biomolecular Medicine
Faculty of Medicine and Health Sciences
Ghent University

Michael W. Pfaffl, PhD
Professor of Molecular Physiology
Animal Physiology & Immunology
School of Life Sciences
Technical University of Munich

Symposium sponsors

September 2020

Human Paths

Archaeology and genetics are starting to resolve humanity’s origin and spread

Marketplace

Sponsored Product Updates

Next-Generation Sequencing (NGS) Sample Preparation
Download this white paper to learn the best practices for optimizing sample homogenization in NGS nucleic acid extraction!
Bio-Rad Introduces StarBright Violet 515 Dyefor Flow Cytometry
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of StarBright Violet 515 (SBV515) Dye, the first of a new range of unique fluorescent nanoparticles, for use in flow cytometry.
Weighing the Benefits of a Clean Balance
Download this reference paper to learn the eight steps to a clean balance!
Predicting and Overcoming Resistance Using IsoPlexis' Single-Cell Intracellular Proteomic and Metabolomic Analysis Tools
Cancer cells develop resistance to targeted therapies, and their inherent functional heterogeneity makes it difficult for researchers to understand and characterize these resistance mechanisms. IsoPlexis' single-cell proteomics is helping researchers overcome resistance to targeted inhibitors, leading to better strategies and combination therapies.